A Test Identifying Biomarkers of Immunosuppression-Related Adverse Events in Kidney Transplant Recipients.
作者信息
Legendre Christophe
机构信息
Service de Néphrologie-Transplantation, Hôpital Necker, Paris, France.
出版信息
Kidney Int Rep. 2019 Oct 31;4(12):1664-1665. doi: 10.1016/j.ekir.2019.10.006. eCollection 2019 Dec.
Abstract
摘要
相似文献
1
A Test Identifying Biomarkers of Immunosuppression-Related Adverse Events in Kidney Transplant Recipients.
Kidney Int Rep. 2019 Oct 31;4(12):1664-1665. doi: 10.1016/j.ekir.2019.10.006. eCollection 2019 Dec.
2
Conversion from Calcineurin Inhibitor- to Belatacept-Based Maintenance Immunosuppression in Renal Transplant Recipients: A Randomized Phase 3b Trial.
J Am Soc Nephrol. 2021 Dec 1;32(12):3252-3264. doi: 10.1681/ASN.2021050628.
3
Fingerprints of transplant tolerance suggest opportunities for immunosuppression minimization.
Clin Biochem. 2016 Mar;49(4-5):404-10. doi: 10.1016/j.clinbiochem.2016.01.007. Epub 2016 Jan 13.
4
Prostate cancer in kidney transplant recipients - a nationwide register study.
BJU Int. 2020 May;125(5):679-685. doi: 10.1111/bju.15002. Epub 2020 Feb 12.
5
Belatacept for kidney transplant recipients.
Cochrane Database Syst Rev. 2014 Nov 24;2014(11):CD010699. doi: 10.1002/14651858.CD010699.pub2.
6
Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
Transpl Immunol. 2008 Nov;20(1-2):32-42. doi: 10.1016/j.trim.2008.08.005. Epub 2008 Sep 4.
7
Immunosuppression Has Long-Lasting Effects on Circulating Follicular Regulatory T Cells in Kidney Transplant Recipients.
Front Immunol. 2020 Aug 28;11:1972. doi: 10.3389/fimmu.2020.01972. eCollection 2020.
8
Steroid-Sparing and Steroid-Based Immunosuppression in Kidney Transplant: Is There a Difference in Outcomes and Recipient Comorbidities?
Exp Clin Transplant. 2020 Oct;18(5):572-576. doi: 10.6002/ect.2020.0067. Epub 2020 Jul 6.
9
Experience with belatacept rescue therapy in kidney transplant recipients.
Transpl Int. 2016 Nov;29(11):1184-1195. doi: 10.1111/tri.12822. Epub 2016 Sep 14.
10
Induction immunosuppression in kidney transplant recipients older than 60 years of age : safety and efficacy of ATGAM, OKT3 and Simulect.
Drugs Aging. 2004;21(11):747-56. doi: 10.2165/00002512-200421110-00005.
本文引用的文献
1
Pretransplant Levels of C-Reactive Protein, Soluble TNF Receptor-1, and CD38+HLADR+ CD8 T Cells Predict Risk of Allograft Rejection in HIV+ Kidney Transplant Recipients.
Kidney Int Rep. 2019 Aug 19;4(12):1705-1716. doi: 10.1016/j.ekir.2019.08.006. eCollection 2019 Dec.
2
TNF-α Production by Monocytes Stimulated With Epstein-Barr Virus-Peptides as a Marker of Immunosuppression-Related Adverse Events in Kidney Transplant Recipients.
Kidney Int Rep. 2019 Jul 19;4(10):1446-1453. doi: 10.1016/j.ekir.2019.07.007. eCollection 2019 Oct.
3
Precision Transplant Medicine: Biomarkers to the Rescue.
J Am Soc Nephrol. 2018 Jan;29(1):24-34. doi: 10.1681/ASN.2017010004. Epub 2017 Oct 9.
4
Moving Biomarkers toward Clinical Implementation in Kidney Transplantation.
J Am Soc Nephrol. 2017 Mar;28(3):735-747. doi: 10.1681/ASN.2016080858. Epub 2017 Jan 6.
5
Establishing Biomarkers in Transplant Medicine: A Critical Review of Current Approaches.
Transplantation. 2016 Oct;100(10):2024-38. doi: 10.1097/TP.0000000000001321.
Zotero 插件